161 related articles for article (PubMed ID: 32359945)
1. Cystic fibrosis 2019: Year in review.
Doull I
Paediatr Respir Rev; 2020 Sep; 35():95-98. PubMed ID: 32359945
[TBL] [Abstract][Full Text] [Related]
2. Clinical papers of the year 2018 - Cystic fibrosis.
Balfour-Lynn IM
Paediatr Respir Rev; 2020 Feb; 33():58-61. PubMed ID: 31053358
[TBL] [Abstract][Full Text] [Related]
3. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
4. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
Elborn JS; Davies J
Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
[No Abstract] [Full Text] [Related]
5. Cystic Fibrosis: Emergence of Highly Effective Targeted Therapeutics and Potential Clinical Implications.
Mall MA; Mayer-Hamblett N; Rowe SM
Am J Respir Crit Care Med; 2020 May; 201(10):1193-1208. PubMed ID: 31860331
[TBL] [Abstract][Full Text] [Related]
6. Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
VanDevanter DR; Mayer-Hamblett N
Curr Opin Pulm Med; 2017 Nov; 23(6):530-535. PubMed ID: 28708817
[TBL] [Abstract][Full Text] [Related]
7. Entering the era of highly effective modulator therapies.
Dave K; Dobra R; Scott S; Saunders C; Matthews J; Simmonds NJ; Davies JC
Pediatr Pulmonol; 2021 Feb; 56 Suppl 1():S79-S89. PubMed ID: 33434412
[TBL] [Abstract][Full Text] [Related]
8. Projecting the impact of delayed access to elexacaftor/tezacaftor/ivacaftor for people with Cystic Fibrosis.
Stanojevic S; Vukovojac K; Sykes J; Ratjen F; Tullis E; Stephenson AL
J Cyst Fibros; 2021 Mar; 20(2):243-249. PubMed ID: 32855088
[TBL] [Abstract][Full Text] [Related]
9. Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.
Ruffin M; Roussel L; Maillé É; Rousseau S; Brochiero E
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L635-L641. PubMed ID: 29351441
[TBL] [Abstract][Full Text] [Related]
10. Eligibility of CFTR modulators for the adult-diagnosed cystic fibrosis population.
Desai S; Lam GY; Sykes J; Stephenson AL; Quon BS
J Cyst Fibros; 2020 Sep; 19(5):840-841. PubMed ID: 32505524
[No Abstract] [Full Text] [Related]
11. AJRCCM: 100-Year Anniversary. Progress along the Pathway of Discovery Leading to Treatment and Cure of Cystic Fibrosis.
Ramsey BW; Welsh MJ
Am J Respir Crit Care Med; 2017 May; 195(9):1092-1099. PubMed ID: 28459323
[No Abstract] [Full Text] [Related]
12. Rapid Improvement after Starting Elexacaftor-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease.
Burgel PR; Durieu I; Chiron R; Ramel S; Danner-Boucher I; Prevotat A; Grenet D; Marguet C; Reynaud-Gaubert M; Macey J; Mely L; Fanton A; Quetant S; Lemonnier L; Paillasseur JL; Da Silva J; Martin C;
Am J Respir Crit Care Med; 2021 Jul; 204(1):64-73. PubMed ID: 33600738
[No Abstract] [Full Text] [Related]
13. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
15. Treating Specific Variants Causing Cystic Fibrosis.
Cutting GR
JAMA; 2017 Dec; 318(21):2130-2131. PubMed ID: 29209709
[No Abstract] [Full Text] [Related]
16. CFTR modulator therapy in patients with cystic fibrosis and an organ transplant.
Mitchell RM; Jones AM; Barry PJ
Paediatr Respir Rev; 2018 Jun; 27():6-8. PubMed ID: 30158080
[TBL] [Abstract][Full Text] [Related]
17. Cystic Fibrosis: The Dawn of a New Therapeutic Era.
Heltshe SL; Cogen J; Ramos KJ; Goss CH
Am J Respir Crit Care Med; 2017 Apr; 195(8):979-984. PubMed ID: 27710011
[No Abstract] [Full Text] [Related]
18. An acneiform eruption associated with elexacaftor/tezacaftor/ivacaftor treatment.
Breneman A; Soliman YS; Gallitano SM
Dermatol Online J; 2021 Nov; 27(11):. PubMed ID: 35130408
[No Abstract] [Full Text] [Related]
19. The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy.
Lommatzsch ST; Taylor-Cousar JL
Ther Adv Respir Dis; 2019; 13():1753466619844424. PubMed ID: 31027466
[TBL] [Abstract][Full Text] [Related]
20. New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Ong T; Ramsey BW
Pediatr Clin North Am; 2016 Aug; 63(4):751-64. PubMed ID: 27469186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
